MERCK
22.5.2024 19:30:28 CEST | Business Wire | Press release
Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire for US$ 600 million. Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®. Transfection reagents play a critical role in the production of viral vector-based gene therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523399185/en/
Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)
“Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years1 and will continue to advance, with a projected growth of 30 percent until 20282,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “This acquisition, combined with our comprehensive portfolio, enables us to provide a truly differentiated and integrated offering to meet the growing demand for these life-saving therapies.”
“We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, CEO of Mirus Bio. “Merck’s broad portfolio, scale and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”
Merck’s Process Solutions business offers one of the broadest product portfolios in the industry and provides flexible solutions for viral vector manufacturing to advance cell and gene therapies from preclinical through commercial production. This comprehensive portfolio includes cell lines, cell culture media, processing chemicals and buffers, enzymes, as well as systems, filters, hardware and consumables to support every step of the viral vector manufacturing processes. Merck’s expertise and portfolio covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, Merck’s Life Science Services business offers both contract testing services and a suite of comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience supporting cell and gene therapies to de-risk the path to commercialization.
This deal is anticipated to close in Q3 of 2024 and is subject to regulatory clearance and other customary closing conditions.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
2 EvaluatePharma 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523399185/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dalton Maag Launches Radically Simplified Font Licensing Model2.3.2026 14:00:00 CET | Press release
Dalton Maag, the independent typeface design studio, today launched a comprehensive overhaul of its retail font licensing structure, consolidating complex rights into four licence types. The new model aims to eliminate ‘licence anxiety’ for creatives and businesses by replacing narrow, technical restrictions with broad, generous permissions. For many years, the font industry has been defined by confusing bundling practices and legal traps. Whether a licence is too granular – forcing buyers to make too many small decisions – or too restrictive – blocking reasonable use – the result is the same: obstacles that hinder rather than enable creativity and communication. Dalton Maag’s new licensing structure directly addresses these challenges. “We’ve seen font licensing become harder to understand and easier to get wrong,” said Lukas Paltram, Executive Creative Director at Dalton Maag. “Our goal was to make licensing as simple as it can be without sacrificing fairness. Designers should be abl
SBC Medical Appoints Sheng-FU Hsiao as CTOLeveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure2.3.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This appointment aligns with the Company’s 2026 management strategy, "Sophistication of Management Structure through AI and DX," and strengthens its leadership team to accelerate technological transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302064873/en/ SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure SBC Medical is transitioning from a traditional labor-intensive management model to an AI-driven infrastructure to address structural challenges in the m
SIMO Expands Carrier Enablement Strategy to Power Resilient, Multi-Network Enterprise Fixed Wireless Access Deployments2.3.2026 13:00:00 CET | Press release
xSIM orchestration delivers cross-network performance and unified global FWA deployment. SIMO, a leader in innovative mobile connectivity solutions, today announced the expansion of its carrier enablement strategy to power resilient, multi-network enterprise Fixed Wireless Access (FWA) deployments for both primary and backup applications. SIMO will showcase its evolution to a carrier enablement platform powering enterprise-grade FWA at Mobile World Congress 2026, in the MediaTek booth (Hall 3, Booth 3D10). “The future of enterprise FWA is not single-network, it is intelligently orchestrated multi-network connectivity,” said Eric Plam, chief revenue officer at SIMO. “By combining AI-driven local network selection with centralized global control, carriers can deliver resilient connectivity at scale while unlocking recurring managed service revenue.” Through SIMO xSIM orchestration operating at both the device firmware layer and the cloud, SIMO enables intelligent multi-network selection,
Venture Global Announces LNG Purchase Agreement with Trafigura2.3.2026 12:02:00 CET | Press release
New 5-year agreement offers flexibility and diversification to LNG portfolio Today, Venture Global, Inc. (NYSE: VG) and Trafigura announced the execution of a new, binding agreement for the purchase of approximately 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026. This mid-term agreement offers greater flexibility to customers in the global LNG market and provides greater diversification for Venture Global’s LNG portfolio. “Trafigura is a global leader in LNG trading, and we are pleased to execute this mid-term LNG supply agreement with them to provide the market with flexible and reliable U.S. LNG,” said Venture Global CEO Mike Sabel. “Global energy demand is stronger than ever, and this is an important step in executing our strategy of adding more mid-term agreements, which will diversify the tenor of our LNG portfolio. Venture Global looks forward to helping ensure the world remains well-supplied in the sh
“AI Realized Through Display” … Samsung Display Showcases AI-Optimized OLED Technologies at MWC262.3.2026 10:58:00 CET | Press release
Introducing “Flex Magic Pixel™,” a panel-integrated privacy technology enabled by low-power, high-brightness LEAD™… Essential smartphone privacy for the AI era’s surge in personalized data usage “Thinner and tougher”… Foldable OLED durability proven with a golf putting challenge “Create your own K-pop concert”… MR experience equipped with 5,000 PPI RGB OLEDoS draws major attention New concept “edge devices” incorporating Samsung Display OLED’s unique free-form, low-power and high-resolution technologies unveiled – including the companion robot concept “Mini PetBot” and the interior décor item “AI Toy House” Spain’s Park Güell tile mosaics recreated through displays using 6.8-inch OLED and 27-inch QD-OLED, highlighting high color reproduction and bezel-less technology Eric Kim, Executive Vice President and Head of Mobile Strategic Marketing: “In the AI era, displays will evolve from simple viewing screens into intelligent interfaces that understand and respond to users and their surroun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom